MARKET

SYNH

SYNH

Syneos Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

70.72
+0.16
+0.23%
After Hours: 70.72 0 0.00% 16:37 05/25 EDT
OPEN
70.24
PREV CLOSE
70.56
HIGH
71.37
LOW
70.05
VOLUME
366.20K
TURNOVER
0
52 WEEK HIGH
104.18
52 WEEK LOW
66.73
MARKET CAP
7.25B
P/E (TTM)
30.60
1D
5D
1M
3M
1Y
5Y
Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 47%?
How far off is Syneos Health, Inc. ( NASDAQ:SYNH ) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 12h ago
Syneos Health to Present at Upcoming Investor Conferences
MORRISVILLE, N.C., May 24, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences. Chief Executive O...
GlobeNewswire · 1d ago
Guggenheim Starts Syneos Health at Buy With $81 Price Target
MT Newswires · 1d ago
Syneos Health Leaders Recognized by HBA
Healthcare Businesswomen’s Association Spotlights Kasey Boynton and Feni Komline for Biopharma Industry ImpactMORRISVILLE, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organizati...
GlobeNewswire · 05/10 13:00
Syneos Health's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Syneos Health (NASDAQ:SYNH) posted Q1 earnings of $46.18 million, an increase from Q4 of 39.21%. Sales dropped to $1.34 billion, a 2.69% decrease between quarters.
Benzinga · 05/06 13:59
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.
Zacks · 05/02 12:31
Syneos Health Shares Jump On Better Than Expected Q1 Earnings, FY22 Outlook
Benzinga · 04/29 19:38
Syneos Health names new CEO as revenues race past $5 billion
The company with about 28,000 employees has a new CEO following a year that saw revenues soar by double digits.
American City Business Journals · 04/29 17:05
More
No Data
Learn about the latest financial forecast of SYNH. Analyze the recent business situations of Syneos Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

18.18%Strong Buy
54.55%Buy
18.18%Hold
9.09%Under-perform
0.00%Sell
Analyst Price Target
The average SYNH stock price target is 95.33 with a high estimate of 115.00 and a low estimate of 76.00.
High115.00
Average95.33
Low76.00
Current 70.72
EPS
Actual
Estimate
0.370.741.111.48
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 495
Institutional Holdings: 132.45M
% Owned: 129.13%
Shares Outstanding: 102.58M
TypeInstitutionsShares
Increased
120
6.50M
New
66
752.69K
Decreased
147
5.04M
Sold Out
41
1.00M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Non-Executive Chairman/Independent Director
John Dineen
Chief Executive Officer/Director
Michelle Keefe
Chief Financial Officer
Jason Meggs
Chief Operating Officer
Michael Brooks
Chief Human Resource Officer
Lisa Van Capelle
General Counsel/Secretary
Jonathan Olefson
Other
Paul Colvin
Independent Director
Todd Abbrecht
Independent Director
Barbara Bodem
Independent Director
Bernadette Connaughton
Independent Director
Linda Harty
Independent Director
William Klitgaard
Independent Director
Kenneth Meyers
Independent Director
Matthew Monaghan
Independent Director
David Wilkes
Independent Director
Alfonso Zulueta
No Data
No Data
About SYNH
Syneos Health, Inc. is a biopharmaceutical solutions company. The Company provides a range of clinical and commercial services to customers in the pharmaceutical, biotechnology, and healthcare industries. It offers both stand-alone and integrated biopharmaceutical product development solutions ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. The Company operates through two business segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers a range of services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings such as clinical monitoring, investigator recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including deployment solutions, communication solutions, and consulting services.

Webull offers kinds of Syneos Health Inc stock information, including NASDAQ:SYNH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYNH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYNH stock methods without spending real money on the virtual paper trading platform.